Link to this page
Medical Subject Headings
Last uploaded:
January 16, 2025
Jump to:
Preferred Name | ambrisentan | |
Synonyms |
LU-208075 (+)-ambrisentan GSK 1325760A (R)-ambrisentan (+)-(2S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid (-)-ambrisentan LU 208075 (+-)-ambrisentan GSK 1325760 ambrisentan, (R)- GSK1325760A BSF 208075 Letairis ambrisentan, (-)- (S)-ambrisentan BSF208075 ambrisentan, (+-)- GSK1325760 LU208075 GSK-1325760 Volibris BSF-208075 GSK-1325760A |
|
ID |
http://purl.bioontology.org/ontology/MESH/C467894 |
|
altLabel |
LU-208075 (+)-ambrisentan GSK 1325760A (R)-ambrisentan (+)-(2S)-2-((4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid (-)-ambrisentan LU 208075 (+-)-ambrisentan GSK 1325760 ambrisentan, (R)- GSK1325760A BSF 208075 Letairis ambrisentan, (-)- (S)-ambrisentan BSF208075 ambrisentan, (+-)- GSK1325760 LU208075 GSK-1325760 Volibris BSF-208075 GSK-1325760A
|
|
cui |
C5544334 C5544335 C5544333 C1949323 C1172101 C1176329 C1259132 C5418144
|
|
HM |
D010666 D011724
|
|
II |
D006976
|
|
Inverse of RB |
7B43003091 Q1BX7HE63A HW6NV07QEC 0
|
|
isa | ||
LT |
TRD
|
|
Mapped to | ||
MDA |
20021115
|
|
MeSH Frequency |
285
|
|
MMR |
20210706
|
|
notation |
C467894
|
|
PA |
D000959
|
|
prefLabel |
ambrisentan
|
|
RR |
7B43003091 177036-94-1 Q1BX7HE63A
|
|
SC |
1
|
|
Scope Statement |
an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension
|
|
SRC |
Clin Sci (Lond) 2002 Aug;103 Suppl 48:408S-413S
|
|
TERMUI |
T001099143 T001099137 T001099139 T001108528 T700173 T544390 T001099148 T001099142 T544388 T001099134 T544389 T001099138 T001099135 T526224 T000910962 T001099149 T544391 T001099136 T001099140 T544392 T001099145 T001099141 T001099144 T544393
|
|
TH |
FDA SRS (2017) USAN (2002) NLM (2021) INN (19XX) NLM (2003) NLM (2017) NLM (2007)
|
|
tui |
T109 T121
|
Add comment
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |
Create mapping